[go: up one dir, main page]

NO20010627D0 - Anvendelse av Gingko Biloba ekstrakter for fremstilling av et medikament for behandling av amyotrofisk lateral sclerose - Google Patents

Anvendelse av Gingko Biloba ekstrakter for fremstilling av et medikament for behandling av amyotrofisk lateral sclerose

Info

Publication number
NO20010627D0
NO20010627D0 NO20010627A NO20010627A NO20010627D0 NO 20010627 D0 NO20010627 D0 NO 20010627D0 NO 20010627 A NO20010627 A NO 20010627A NO 20010627 A NO20010627 A NO 20010627A NO 20010627 D0 NO20010627 D0 NO 20010627D0
Authority
NO
Norway
Prior art keywords
lateral sclerosis
amyotrophic lateral
drug
preparation
treatment
Prior art date
Application number
NO20010627A
Other languages
English (en)
Other versions
NO20010627L (no
NO327733B1 (no
Inventor
Yves Christen
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of NO20010627L publication Critical patent/NO20010627L/no
Publication of NO20010627D0 publication Critical patent/NO20010627D0/no
Publication of NO327733B1 publication Critical patent/NO327733B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20010627A 1998-08-07 2001-02-06 Anvendelse av Gingko biloba-ekstrakter for fremstilling av et medikament for behandling av amyotrofisk lateral sklerose NO327733B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9810187A FR2782008B1 (fr) 1998-08-07 1998-08-07 Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique
PCT/FR1999/001948 WO2000007592A1 (fr) 1998-08-07 1999-08-06 Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique

Publications (3)

Publication Number Publication Date
NO20010627L NO20010627L (no) 2001-02-06
NO20010627D0 true NO20010627D0 (no) 2001-02-06
NO327733B1 NO327733B1 (no) 2009-09-14

Family

ID=9529516

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010627A NO327733B1 (no) 1998-08-07 2001-02-06 Anvendelse av Gingko biloba-ekstrakter for fremstilling av et medikament for behandling av amyotrofisk lateral sklerose

Country Status (12)

Country Link
US (1) US6524629B1 (no)
EP (1) EP1102586B1 (no)
JP (1) JP4510289B2 (no)
AT (1) ATE281162T1 (no)
AU (1) AU5170499A (no)
CA (1) CA2340021C (no)
DE (1) DE69921662T2 (no)
ES (1) ES2230873T3 (no)
FR (1) FR2782008B1 (no)
NO (1) NO327733B1 (no)
PT (1) PT1102586E (no)
WO (1) WO2000007592A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2785808B1 (fr) * 1998-11-13 2002-12-06 Aventis Laboratoire Association riluzole et alpha-tocopherol
FR2827518B1 (fr) * 2001-07-17 2005-07-08 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sarcopenie
JP4528490B2 (ja) * 2002-06-25 2010-08-18 和光化学株式会社 ギンコライド−ａを含有する抗不安剤
WO2004074024A2 (en) 2003-02-19 2004-09-02 Pilkington North America, Inc. Powered slider drive interface and drive assembly
WO2004098519A2 (en) * 2003-05-02 2004-11-18 Georgetown University Ginkgo biloba extract as a treatment for therapeutic­ induced neurotoxicity
WO2006004386A1 (es) * 2004-07-02 2006-01-12 Rojas Castaneda Patricia Uso de un extracto del ginkgo biloba para preparar una medicina para tratar la enfermedad de parkinson
CA2624567A1 (en) * 2005-09-30 2007-04-12 Kinemed, Inc. Microtubule synthesis as a biomarker
US8883847B2 (en) * 2006-01-05 2014-11-11 Kinemed, Inc. Compositions and methods of treatment using modulators of motoneuron diseases
FR2904222A1 (fr) 2006-07-27 2008-02-01 Sod Conseils Rech Applic Utilisation d4extraits de ginkgo biloba pour le traitement de maladies mitochondriales
JP2011523848A (ja) * 2008-05-21 2011-08-25 キネメッド， インコーポレイテッド 運動ニューロン疾患の調節物質を用いる処置方法および組成物
GB0922064D0 (en) 2009-12-17 2010-02-03 Pilkington Group Ltd Soda lime silica glass composition
WO2013108926A1 (en) * 2012-01-17 2013-07-25 Kyoto University Prophylactic and therapeutic drug for amyotrophic lateral sclerosis and method of screening therefor
WO2016114655A1 (en) * 2015-01-12 2016-07-21 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
WO2017065602A1 (en) * 2015-10-13 2017-04-20 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
CN108096243B (zh) * 2017-11-24 2020-05-29 江苏康缘药业股份有限公司 银杏内酯组合物的医药用途
CN110893183A (zh) * 2018-09-13 2020-03-20 成都百裕制药股份有限公司 银杏萜内酯在制备预防、缓解或治疗肌萎缩侧索硬化药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3338995A1 (de) * 1983-10-27 1985-05-09 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe Bilobalid enthaltende arzneimittel
DE3940094A1 (de) * 1989-12-04 1991-06-06 Montana Ltd Wirkstoffkonzentrate und neue wirkstoff-kombinationen aus blaettern von ginkgo biloba, ein verfahren zu ihrer herstellung und die wirkstoff-konzentrate bzw. die wirkstoff-kombinationen enthaltenden arzneimittel
DE4328374A1 (de) * 1993-08-24 1995-03-02 Deinlein Kalb Hans Neue Verwendung eines Extraktes aus den Blättern von Ginkgo biloba
CZ293360B6 (cs) * 1995-10-26 2004-04-14 Sanofi-Synthelabo Léčivo pro léčení amyotrofické laterální sklerózy

Also Published As

Publication number Publication date
DE69921662T2 (de) 2005-10-20
CA2340021C (fr) 2009-09-15
AU5170499A (en) 2000-02-28
ES2230873T3 (es) 2005-05-01
US6524629B1 (en) 2003-02-25
NO20010627L (no) 2001-02-06
FR2782008B1 (fr) 2003-04-25
ATE281162T1 (de) 2004-11-15
PT1102586E (pt) 2005-02-28
NO327733B1 (no) 2009-09-14
EP1102586A1 (fr) 2001-05-30
JP2002522387A (ja) 2002-07-23
DE69921662D1 (de) 2004-12-09
CA2340021A1 (fr) 2000-02-17
JP4510289B2 (ja) 2010-07-21
EP1102586B1 (fr) 2004-11-03
FR2782008A1 (fr) 2000-02-11
WO2000007592A1 (fr) 2000-02-17

Similar Documents

Publication Publication Date Title
NO20010627L (no) Anvendelse av Gingko Biloba ekstrakter for fremstilling av et medikament for behandling av amyotrofisk lateral sclerose
WO1994027589A3 (en) Antidepressant dosage form
ATE265857T1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
AU6311301A (en) Drug/drug delivery systems for the prevention and treatment of vascular disease
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
ZA200300712B (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and Behcet's syndrome.
WO2001030335A3 (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
EE03663B1 (et) Rinnavähi vältimise meetod, farmatseutiline preparaat ja toode ning toimeaine kasutamine
DE60002226D1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von kreislaufstörungen, enthaltend l-carnitin derivate und ginkgo biloba extrakte
FR2827518B1 (fr) Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sarcopenie
DE69918961D1 (de) Verbesserte inhalationspräparate
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
EP0744176A3 (en) Methods for inhibiting bone loss
AU2636602A (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
WO2003018535A3 (en) Novel aminobenzoephenones
DE69823226D1 (de) Pharmazeutische zusammmensetzung, enthaltend ticlopidin und ginkgo biloba extrakt
FR2842425B1 (fr) Utilisation d'extraits de ginkgo biloba pour favoriser la masse musculaire au detriment de la masse graisseuse
DE69918339D1 (de) Pharmazeutische zusammensetzungen die selegilin und ginkgo biloba extrakt enthalten zur behandlung von demenz
HUP9902469A3 (en) Use of ginkgo biloba extracts for the preparation of pharmaceutical compositions, and method of cosmetic treatment using a ginkgo biloba extract
HU9802896D0 (en) Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
HU206985B (en) Process for producing vitalizing composition comprising gingko biloba extracts as main medicinal herb active ingredient
IT1304852B1 (it) Miscela di piante medicinali per la prevenzione e la cura delleemorroidi.
SI1313489T1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees